Should I Buy crisper Technologies (CRSP)? Finance YouTuber Analysis

This creator highlights CRISPR Therapeutics as a key example of a company developing gene-editing therapies for common conditions like cardiovascular disease, moving beyond rare diseases. They note encouraging proof-of-concept phase one data and anticipate further positive developments, driven by the targeting of genes important in liver metabolism.

“I can highlight one key example actually that we're focused around and that's crisper therapeutics. So they're developing gene editing therapies that can address just this right moving from not just you know success in rare diseases but also very common conditions such as cardiovascular disease by targeting genes that play a very important role in liver metabolism.”

This creator is bullish on CRISPR Therapeutics due to its focus on curing type 1 and type 2 diabetes, which could be a 'category killer' cure. They believe that cures, despite traditional market skepticism, should be valued significantly higher than chronic disease treatments, driving substantial returns for companies embracing these new technologies.

“in fact crisper Therapeutics is focused on type one diabetes and type two diabetes which would be the cat category killer uh for this particular cure”

Wood highlights CRISPR Therapeutics as a company already curing diseases like sickle cell and beta thalassemia with approved drugs in the US, UK, and Europe. She argues that the market misunderstands the transformative potential of such innovation in healthcare, especially with AI applications, and expects a shift in perception.

“CRISPR Therapeutics is a company that's whose drugs have been approved in both US and the UK and Europe as a matter of fact those three areas curing CLE cell disease and beta Thalia.”

This creator highlights CRISPR Therapeutics as another undervalued gene-editing company, with its therapies for sickle cell disease and beta-thalassemia already approved and generating revenue. They believe the market is underestimating the revenue potential and transformative impact of these curative treatments, which offer a fundamentally different and more valuable revenue curve compared to traditional drugs.

“CRISPR Therapeutics which you did mention early on sickle cell disease beta thymia, these therapies have been approved in the US, UK and Europe and the patients are entering the trial or or or being dosed now I should say, so we're going to see real revenue recognition when CRISPR reports.”

This creator highlights CRISPR Therapeutics' recent FDA approval for Casgevy, a gene-editing therapy for sickle cell disease, as a significant breakthrough. They believe this marks the beginning of a new era in gene editing, with potential for future applications in larger indications like diabetes and cardiovascular diseases, despite the long clinical trial process.

“the first ever Gene editing approval was uh given to crisper Therapeutics and vertex Pharmaceuticals for a uh medicine called kevi”

Cathie Wood points to Crispr Therapeutics as a company working on gene editing to cure chronic diseases like diabetes. She emphasizes the potential for outright cures in healthcare through the convergence of DNA sequencing, AI, and gene editing, which could solve major budget issues related to chronic conditions.

“We're seeing companies like Crispr Therapeutics and Vertex working with gene editing to cure diabetes which is from a chronic set of conditions one of the biggest budget busters of all.”

The YouTuber recommends Crispr Technologies as a leader in gene editing, highlighting its approved programs for sickle cell disease and beta-thalassemia, and a strong pipeline. He notes the company's significant cash reserves to fund development despite currently operating at a loss.

“further along than most companies in this is crisper Technologies ticker crsp with programs already approved for Cle cell disease and phemia”